litlas
Log inCreate account

Keith S. Kaye

Active 1995–2025

187
Papers
28,792
Citations
95
h-index
177
i10-index

Citations

Citations per year for Keith S. Kaye1936: 1 citations1986: 2 citations1987: 1 citations1990: 2 citations1991: 1 citations1992: 2 citations1995: 1 citations1996: 2 citations1997: 2 citations1998: 5 citations1999: 1 citations2000: 3 citations2001: 5 citations2002: 7 citations2003: 23 citations2004: 45 citations2005: 84 citations2006: 112 citations2007: 122 citations2008: 126 citations2009: 148 citations2010: 153 citations2011: 137 citations2012: 149 citations2013: 188 citations2014: 206 citations2015: 174 citations2016: 231 citations2017: 217 citations2018: 190 citations2019: 1,024 citations2020: 1,023 citations2021: 1,015 citations2022: 843 citations2023: 705 citations2024: 1,281 citations2025: 581 citations2026: 14 citations1937–1985: no citations, so these years are not shown1988–1989: no citations, so these years are not shown1993–1994: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,521 citing papers, 25.3% of this breakdownChina: 848 citing papers, 8.5% of this breakdownItaly: 524 citing papers, 5.3% of this breakdownUnited Kingdom: 484 citing papers, 4.9% of this breakdownSpain: 412 citing papers, 4.1% of this breakdownAustralia: 370 citing papers, 3.7% of this breakdownCanada: 322 citing papers, 3.2% of this breakdownFrance: 322 citing papers, 3.2% of this breakdownGermany: 279 citing papers, 2.8% of this breakdownIndia: 222 citing papers, 2.2% of this breakdownSwitzerland: 201 citing papers, 2% of this breakdownGreece: 188 citing papers, 1.9% of this breakdown
0%25.3%Other 32.9%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology44.2%
  • Medicine42.5%
  • Immunology and Microbiology5.7%
  • Health Professions1.8%
  • Environmental Science1.4%
  • Agricultural and Biological Sciences0.9%
  • Other3.5%

Topics

  • Antibiotic Resistance in Bacteria16.6%
  • Antibiotics Pharmacokinetics and Efficacy8.4%
  • Antibiotic Use and Resistance6.5%
  • Bacterial Identification and Susceptibility Testing4.6%
  • Nosocomial Infections in ICU4.5%
  • Antimicrobial Resistance in Staphylococcus4.2%
  • Other55.2%

Coauthors

All papers

Open in search
  1. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)

    Authors: Brian T. Tsuji, Jason M. Pogue, Alexandre Prehn Zavascki, Mical Paul, George L. Daikos, Alan Forrest, Daniele Roberto Giacobbe, Claudio Viscoli, Helen Giamarellou, Ilias Karaiskos, Donald Kaye, Johan W. Mouton, Vincent H. Tam, Visanu Thamlikitkul, Richard G. Wunderink, Jian Li, Roger L. Nation, Keith S. Kaye - Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy 2019 cited by 931

  2. Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)

    Authors: Keith S. Kaye, Andrew F. Shorr, Richard G. Wunderink, Bin Du, Gabrielle Poirier, Khurram Rana, Alita A. Miller, Drew Lewis, John P. O’Donnell, Lan Chen, Harald H. Reinhart, Subasree Srinivasan, Robin Isaacs, David Altarac - The Lancet Infectious Diseases 2023 cited by 286

  3. Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study

    Authors: Jinnethe Reyes, Lauren Komarow, Liang Chen, Lizhao Ge, Blake Hanson, Eric Cober, Erica Herc, Thamer H. Alenazi, Keith S. Kaye, Julia Garcia‐Diaz, Lanjuan Li, Souha S. Kanj, Zhengyin Liu, Jose M Oñate, Robert A. Salata, Kalisvar Marimuthu, Hainv Gao, Zhiyong Zong, Sandra Valderrama, Yunsong Yu, Paul Anantharajah Tambyah, Gregory Weston, Soraya Salcedo, Lillian M Abbo, Qing Xie, Karen Ordóñez, Minggui Wang, Martín E. Stryjewski, José M. Munita, David L. Paterson, Scott Evans, Carol Hill, Keri Baum, Robert A. Bonomo, Barry N. Kreiswirth, María Virginia Villegas, Robin Patel, César A. Arias, Henry F. Chambers, Vance G. Fowler, Yohei Doi, David van Duin, Michael J. Satlin, Jinnethe Reyes, Lauren Komarow, Liang Chen, Lizhao Ge, Blake Hanson, Eric Cober, Erica Herc, Thamer H. Alenazi, Keith S. Kaye, Julia Garcia‐Diaz, Lanjuan Li, Souha S. Kanj, Zhengyin Liu, Jose M Oñate, Robert A. Salata, Kalisvar Marimuthu, Hainv Gao, Zhiyong Zong, Sandra Valderrama, Yunsong Yu, Paul Anantharajah Tambyah, Gregory Weston, Soraya Salcedo, Lillian M Abbo, Qing Xie, Karen Ordóñez, Minggui Wang, Martín E. Stryjewski, José M. Munita, David L. Paterson, Scott Evans, Carol Hill, Keri Baum, Robert A. Bonomo, Barry N. Kreiswirth, María Virginia Villegas, Robin Patel, César A. Arias, Henry F. Chambers, Vance G. Fowler, Yohei Doi, David van Duin, Michael J. Satlin - The Lancet Microbe 2023 cited by 291

  4. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

    Authors: Richard G. Wunderink, Yuko Matsunaga, Mari Ariyasu, Philippe Clevenbergh, Roger Echols, Keith S. Kaye, Marin H. Kollef, Anju Menon, Jason M. Pogue, Andrew F. Shorr, Jean‐François Timsit, Markus Zeitlinger, Tsutae Den Nagata - The Lancet Infectious Diseases 2020 cited by 464

  5. Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study

    Authors: Minggui Wang, Michelle Earley, Liang Chen, Blake Hanson, Yunsong Yu, Zhengyin Liu, Soraya Salcedo, Eric Cober, Lanjuan Li, Souha S. Kanj, Hainv Gao, José M. Munita, Karen Ordóñez, Greg Weston, Michael J. Satlin, Sandra Valderrama, Kalisvar Marimuthu, Martín E. Stryjewski, Lauren Komarow, Courtney Luterbach, Steve H. Marshall, Susan D. Rudin, Claudia Manca, David L. Paterson, Jinnethe Reyes, María Virginia Villegas, Scott Evans, Carol Hill, Rebekka M. Arias, Keri Baum, Bettina C. Fries, Yohei Doi, Robin Patel, Barry N Kreiswirth, Robert A. Bonomo, Henry F. Chambers, Vance G. Fowler, César A. Arias, David van Duin, Lilian M. Abbo, Deverick J. Anderson, Rebekka M. Arias, César A. Arias, Keri Baum, Robert A. Bonomo, Henry F. Chambers, Liang Chen, Kean Lee Chew, Eric Cober, H. R. Cross, Partha Pratim De, Samit Desai, Sorabh Dhar, Valentina Di Castelnuovo, Lorena Díaz, An Q Dinh, Yohei Doi, Michelle Earley, Brandon Eilertson, Beth Evans, Scott Evans, Vance G. Fowler, Bettina C. Fries, Hainv Gao, Julia Garcia‐Diaz, Omai B. Garner, Kerryl E. Greenwood‐Quaintance, Blake Hanson, Erica Herc, Carol Hill, Jesse T. Jacob, Jianping Jiang, Robert C. Kalayjian, Souha S. Kanj, Keith S. Kaye, Angela Kim, Lauren Komarow, Barry N Kreiswirth, Courtney Lauterbach, Lanjuan Li, Zhengyin Liu, Claudia Manca, Kalisvar Marimuthu, Steven H. Marshall, Todd P McCarty, José M. Munita, Oon Tek Ng, Jose Millan Oñate Gutierrez, Karen Ordóñez, Robin Patel, David L. Paterson, Anton Y. Peleg, Jinnethe Reyes, Susan D. Rudin, Robert A. Salata, Soraya Salcedo, Michael J. Satlin, Suzannah M. Schmidt-Malan, Nares Smitasin, María Spencer and 14 more - The Lancet Infectious Diseases 2021 cited by 339

  6. Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study

    Authors: David van Duin, César A. Arias, Lauren Komarow, Liang Chen, Blake Hanson, Gregory Weston, Eric Cober, Omai B. Garner, Jesse T. Jacob, Michael J. Satlin, Bettina C. Fries, Julia Garcia‐Diaz, Yohei Doi, Sorabh Dhar, Keith S. Kaye, Michelle Earley, Andrea M. Hujer, Kristine M. Hujer, Tatiana Domitrovic, William C. Shropshire, An Q Dinh, Claudia Manca, Courtney Luterbach, Minggui Wang, David L. Paterson, Ritu Banerjee, Robin Patel, Scott Evans, Carol Hill, Rebekka M. Arias, Henry F. Chambers, Vance G. Fowler, Barry N. Kreiswirth, Robert A. Bonomo - The Lancet Infectious Diseases 2020 cited by 330

  7. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae

    Authors: David van Duin, Judith J. Lok, Michelle Earley, Eric Cober, Sandra S. Richter, Federico Pérez, Robert A. Salata, Robert C. Kalayjian, Richard Watkins, Yohei Doi, Keith S. Kaye, Vance G. Fowler, David L. Paterson, Robert A. Bonomo, Scott Evans, Antibacterial Resistance Leadership Group - Clinical Infectious Diseases 2017 cited by 652

  8. RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections

    Authors: J. Motsch, Cláudia Murta de Oliveira, V.P. Stus, İftihar Köksal, O. O. Lyulko, Helen W. Boucher, Keith S. Kaye, Thomas M. File, Michelle Brown, Ireen Khan, Jiejun Du, Hee‐Koung Joeng, Robert Tipping, Angela Aggrey, Katherine Young, Nicholas A. Kartsonis, Joan R. Butterton, Amanda Paschke - Clinical Infectious Diseases 2019 cited by 404

  9. Health Care–Associated Bloodstream Infections in Adults: A Reason To Change the Accepted Definition of Community-Acquired Infections

    Authors: N. Deborah Friedman, Keith S. Kaye, Jason E. Stout, Sarah A. McGarry, Sharon L. Trivette, Jane P. Briggs, Wanda Lamm, Connie Clark, Jennifer MacFarquhar, Aaron L. Walton, L. Barth Reller, Daniel J. Sexton - Annals of Internal Medicine 2002 cited by 1,665

  10. Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

    Authors: Richard G. Wunderink, Evangelos J. Giamarellos‐Bourboulis, Galia Rahav, Amy J. Mathers, Matteo Bassetti, José A. Vázquez, Oliver A. Cornely, Joseph S. Solomkin, Tanaya Bhowmick, Jihad Bishara, George L. Daikos, Tim Felton, María José López Furst, E.J. Kwak, Francesco Menichetti, Ilana Oren, Elizabeth Alexander, David C. Griffith, Olga Lomovskaya, Jeffery S. Loutit, Shu Zhang, Michael N. Dudley, Keith S. Kaye - Infectious Diseases and Therapy 2018 cited by 442

  11. Diabetes and Risk of Surgical Site Infection: A Systematic Review and Meta-analysis

    Authors: Emily T. Martin, Keith S. Kaye, Caitlin Knott, Huong Nguyen, Maressa Santarossa, Richard B. Evans, Elizabeth A. Bertran, Linda A. Jaber - Infection Control and Hospital Epidemiology 2015 cited by 648

  12. Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms

    Authors: Keith S. Kaye, Dror Marchaim, Visanu Thamlikitkul, Yehuda Carmeli, Cheng‐Hsun Chiu, George L. Daikos, Sorabh Dhar, Emanuele Durante‐Mangoni, Achilleas Gikas, Αναστασία Κοτανίδου, Mical Paul, Emmanuelle Roilides, Michael J. Rybak, Michael Samarkos, Matthew Sims, Dora Tancheva, Sotirios Tsiodras, Daniel H. Kett, Gopi Patel, David P. Calfee, Leonard Leibovici, Laura E. Power, L. Silvia Muñoz-Price, Kurt Stevenson, Laura Susick, Katie Latack, Jolene Daniel, Christine C. Chiou, George Divine, Varduhi Ghazyaran, Jason M. Pogue - NEJM Evidence 2022 cited by 143

  13. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection

    Authors: Keith S. Kaye, Tanaya Bhowmick, Symeon Metallidis, Susan C Bleasdale, Olexiy Sagan, V.P. Stus, José A. Vázquez, В. І. Зайцев, Mohamed Bidair, Erik Chorvat, Petru Octavian Drăgoescu, Elena Fedosiuk, Juan Pablo Horcajada, Claudia Murta, Y. V. Sarychev, Ventsislav Stoev, Elizabeth E. Morgan, Karen Fusaro, David C. Griffith, Olga Lomovskaya, Elizabeth Alexander, Jeffery S. Loutit, Michael N. Dudley, Evangelos J. Giamarellos‐Bourboulis - JAMA 2018 cited by 306

  14. Strategies to prevent surgical site infections in acute-care hospitals: 2022 Update

    Authors: Michael S. Calderwood, Deverick J. Anderson, Dale W. Bratzler, E. Patchen Dellinger, Sylvia Garcia‐Houchins, Lisa L. Maragakis, Ann‐Christine Nyquist, Kiran M. Perkins, Michael Anne Preas, Lisa Saiman, Joshua K. Schaffzin, Marin L. Schweizer, Deborah S. Yokoe, Keith S. Kaye - Infection Control and Hospital Epidemiology 2023 cited by 257

  15. A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

    Authors: Ivan Titov, Richard G. Wunderink, Antoine Roquilly, Daniel González, Aileen David-Wang, Helen W. Boucher, Keith S. Kaye, Maria C Losada, Jiejun Du, Robert Tipping, Matthew L. Rizk, Munjal Patel, Michelle Brown, Katherine Young, Nicholas A. Kartsonis, Joan R. Butterton, Amanda Paschke, Luke F. Chen - Clinical Infectious Diseases 2020 cited by 225

  16. In critically ill patients, anti-anaerobic antibiotics increase risk of adverse clinical outcomes

    Authors: Rishi Chanderraj, Jennifer M. Baker, Stephen G. Kay, Christopher A. Brown, Kevin J. Hinkle, Daniel J. Fergle, Roderick A. McDonald, Nicole R. Falkowski, Joseph D. Metcalf, Keith S. Kaye, Robert J. Woods, Hallie C. Prescott, Michael W. Sjoding, Robert P. Dickson - European Respiratory Journal 2022 cited by 129

  17. Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions

    Authors: Minggui Wang, Lizhao Ge, Liang Chen, Lauren Komarow, Blake Hanson, Jinnethe Reyes, Eric Cober, Thamer H. Alenazi, Zhiyong Zong, Qing Xie, Zhengyin Liu, Lanjuan Li, Yunsong Yu, Hainv Gao, Souha S. Kanj, Jairo Figueroa, Erica Herc, Ezequiel Córdova, Gregory Weston, Paul Anantharajah Tambyah, Julia Garcia‐Diaz, Keith S. Kaye, Sorabh Dhar, José M. Munita, Robert A. Salata, Samuel Vilchez, Martín E. Stryjewski, María Virginia Villegas, Alina Iovleva, Scott Evans, Keri Baum, Carol Hill, Barry N. Kreiswirth, Robin Patel, David L. Paterson, Cesar A Arias, Robert A. Bonomo, Henry F. Chambers, Vance G. Fowler, Michael J. Satlin, David van Duin, Yohei Doi, Multi-Drug Resistant Organism Network Investigators, Souha S. Kanj, Fujie Zhang, Judith J. Lok, Robert A. Salata, Martín E. Stryjewski, Valentina Di Castelnuovo, Jose Millan Oñate Gutierrez, Eric Cober, Susan Richter, Deverick J. Anderson, Beth Evans, Carol Hill, H. R. Cross, Keri Baum, Rebekka M. Arias, Vance G Fowler, Karen Ordóñez, Jesse T. Jacob, Linghua Li, Barry N Kreiswirth, Claudia Manca, Liang Chen, Samit Desai, Erica Herc, Ezequiel Córdova, María Luisa Rioseco, Samuel Vilchez, Marisa Sánchez, Sandra Valderrama, Jairo Figueroa, Cesar A Arias, An Q Dinh, Diane Panesso, Kirsten Rydell, Truc T. Tran, Fupin Hu, Jiachun Su, Jianping Jiang, Minggui Wang, Xiaogang Xu, Yang Yang, José M. Munita, María Spencer, Thamer H. Alenazi, Robert A. Bonomo, Steven H. Marshall, Susan D. Rudin, W. Charles Huskins, Kerry Greenwood-Quaintance, Robin Patel, Suzannah M. Schmidt-Malan, Sara Revolinski, Glenn Wortmann, Robert C. Kalayjian, Gregory Weston, Belinda Ostrowsky, Gopi Patel and 48 more - Clinical Infectious Diseases 2023 cited by 94

  18. Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis

    Authors: Keith S. Kaye, Adam Belley, Philip Barth, Omar Lahlou, Philipp Knechtle, Paola Motta, Patrick Vélicitat - JAMA 2022 cited by 117

  19. Strategies to Prevent Surgical Site Infections in Acute Care Hospitals: 2014 Update

    Authors: Deverick J. Anderson, Kelly Podgorny, Sandra I. Berríos-Torres, Dale W. Bratzler, E. Patchen Dellinger, Linda Greene, Ann-Christine Nyquist, Lisa Saiman, Deborah S. Yokoe, Lisa L. Maragakis, Keith S. Kaye - Infection Control and Hospital Epidemiology 2014 cited by 1,205

  20. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa

    Authors: Jason M. Pogue, Keith S. Kaye, Michael P. Veve, Twisha S Patel, Anthony T. Gerlach, Susan L. Davis, Laura Puzniak, T. M. File, Shannon Olson, Sorabh Dhar, Robert A. Bonomo, Federico Pérez - Clinical Infectious Diseases 2019 cited by 205

  21. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus

    Authors: Roger L. Nation, Jian Li, Otto Cars, William Couet, Michael N. Dudley, Keith S. Kaye, Johan W. Mouton, David L. Paterson, Vincent H. Tam, Ursula Theuretzbacher, Brian T. Tsuji, John Turnidge - The Lancet Infectious Diseases 2014 cited by 343

  22. Antimicrobial Resistance Trends in Urine Escherichia coli Isolates From Adult and Adolescent Females in the United States From 2011 to 2019: Rising ESBL Strains and Impact on Patient Management

    Authors: Keith S. Kaye, Vikas Gupta, Aruni Mulgirigama, Ashish V. Joshi, Nicole E. Scangarella-Oman, Kalvin Yu, Gang Ye, Fanny S Mitrani-Gold - Clinical Infectious Diseases 2021 cited by 135

  23. Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial

    Authors: Michael S. Niederman, Jeff Alder, Matteo Bassetti, Francis Boateng, Bin Cao, K Corkery, Rajiv Dhand, Keith S. Kaye, Robert Lawatscheck, Patrick McLeroth, David P. Nicolau, Chen Wang, G. Christopher Wood, Richard G. Wunderink, Jean Chastre - The Lancet Infectious Diseases 2019 cited by 131

  24. Current Epidemiology, Etiology, and Burden of Acute Skin Infections in the United States

    Authors: Keith S. Kaye, Lindsay A Petty, Andrew F. Shorr, Marya D. Zilberberg - Clinical Infectious Diseases 2019 cited by 176